Buy buy sell sell sell
Selling assets into pharmaceutical companies to save performance "good medicine"?
Guangzhou Daily News (photographed by Tu Duanyu, an all-media reporter) Just recently, many pharmaceutical companies have launched a "slimming" model-transfer and sale of their assets or equity, even if the transfer is unsuccessful, they insist on continuing to the end.
Laimei Pharmaceutical, Renfu Pharmaceutical, Harbin Pharmaceuticals, Hisun Pharmaceuticals and other listed companies are all selling assets one by one. Many of them are called "accelerate the development of the main business and avoid the generation of peers with controlling shareholders." competition".
In this regard, some industry observers believe that the sale of assets has always been a shortcut to improve performance. Under the pressure of the new crown pneumonia epidemic this year, many pharmaceutical companies have to rely on this trick to "draw salaries from the bottom" to try their best to keep their performance.
Not only domestic pharmaceutical companies, but some multinational pharmaceutical companies are also making strategic shifts by selling factories and former star drugs.
A number of listed companies recently collectively "slim down"
At the beginning of this month, the equity of the four subsidiaries of Laimei Pharmaceutical was again listed on the Chongqing United Property Rights Exchange for transfer.
This is the 8th time that Laimei Pharmaceutical has transferred the equity of these 4 subsidiaries. The previous 7 transfers were unsuccessful.
It is reported that the target shares to be transferred are 100% of Hunan Kangyuan Pharmaceutical Co., Ltd., with a transfer price of 200 million yuan; Sichuan Hezheng Pharmaceutical Co., Ltd. 100% of shares, with a transfer price of 110 million yuan; Chongqing Laimei Health Industry Co., Ltd. 60 % Equity, the transfer base price is 0.0001 million yuan; Chongqing Laimei Golden Rat Chinese Medicine Decoction Pieces Co., Ltd. 70% equity, the transfer base price is 12.55 million yuan.
Laimei Pharmaceutical's semi-annual report this year showed that in the first half of the year, its operating income was 598 million yuan, a year-on-year decrease of 24%; the net profit loss of equity was 8.1 million yuan, a year-on-year drop of 115%.
Regarding this transaction, Laimei Pharmaceuticals stated that "continuing to publicly dispose of the underlying equity is the company's need to accelerate the development of its main business and avoid horizontal competition with controlling shareholders."
Laimei Pharmaceuticals is not the case. This year, affected by the new crown pneumonia epidemic and domestic pharmaceutical policies, many pharmaceutical companies have suffered a decline in performance.
Last month, Donge Ejiao released a semi-annual report, and its revenue and profit both fell.
On the day of the performance announcement, Donge Ejiao announced that it would transfer its 25% stake in China Resources Onde Biopharmaceutical Co., Ltd. to China Resources Biopharmaceuticals.
It is reported that this connected transaction has little effect on the company's overall income, but it can recover the equity investment of RMB 74,408,425 to increase its cash flow.
A Guangzhou specialist told reporters: In the first half of this year, the sales of non-anti-epidemic drugs in hospital channels were not ideal.
According to incomplete statistics, many well-known pharmaceutical companies such as Harbin Pharmaceutical Co., Ltd., Hisun Pharmaceutical, Tai'antang, Donge Ejiao, Northeast Pharmaceutical, Betta Pharmaceuticals, Renfu Pharmaceutical, Tasly, etc. have recently sold assets in different forms. Actively "slim down", or to accelerate the flow of funds and make the book performance better.
Insiders: The company may lose weight or shift due to strategy
"In fact, the pharmaceutical industry has very frequent transactions. Not only domestic companies, including multinational companies, but also divestiture and sell entire business departments or star drugs. This kind of active reduction of the plate does not necessarily mean that the sun is over, but only that it happened. Strategic shift.” In this regard, industry observers said.
Just this month, Jiuzhou Pharmaceutical intends to raise no more than 1 billion yuan for the development of Ruibo (Suzhou) Pharmaceutical Co., Ltd. and other related projects, and Ruibo (Suzhou) Pharmaceutical has invested about 790 million yuan last year. After the self-raised acquisition of 100% equity of Suzhou Novartis after the divestiture of technology and drug development assets held by Novartis Investments, it was renamed; Coincidentally, GSK also sold its once blockbuster variety Hepuding before, when the product faced For issues such as patent expiration and increasing competitors, GSK first adopted the strategy of "price-for-quantity", and then decided to sell it after its economic efficiency weakened.